InsiderPulseNo transactions found.
| Metric | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Net revenue | $46.7M+22.9% | $38.0M+21.4% | $31.3M+32.9% | $23.6M |
| Cost of revenue | $15.7M+45.2% | $10.8M+197.1% | $3.6M+69.1% | $2.1M |
| Research and development | $12.7M+40.8% | $9.1M-1.6% | $9.2M-7.6% | $10.0M |
| Selling, general and administrative | $119.6M+84.4% | $64.9M+28.3% | $50.6M+17.7% | $43.0M |
| Intangible amortization | $4.1M+4.7% | $3.9M+4.9% | $3.7M+0.0% | $3.7M |
| Total operating costs and expenses | $152.2M+71.6% | $88.7M+32.0% | $67.2M+14.2% | $58.8M |
| Loss from operations | -$105.4M-108.2% | -$50.6M-41.3% | -$35.8M-1.6% | -$35.3M |
| Loss (gain) on derivative liability | $512K+106.2% | -$8.3M-2870.0% | $300K+137.5% | -$800K |
| Change in fair value of debt and liability instruments | $7.2M | $0 | $0 | — |
| Gain on debt extinguishment, net | $0+100.0% | -$28.6M-329.8% | $12.5M | $0 |
| Scilex Pharma Notes principal increase | $0 | $0-100.0% | $28.0M | $0 |
| Interest expense, net | $1.1M-88.9% | $9.6M-18.4% | $11.8M-10.3% | $13.1M |
| Loss on foreign currency exchange | $118K+78.8% | $66K+22.2% | $54K+2800.0% | -$2K |
| Total other (income) expense | $8.9M+132.6% | -$27.3M-151.9% | $52.6M+327.0% | $12.3M |
| Loss before income taxes | -$114.3M-389.4% | -$23.4M+73.6% | -$88.4M-85.9% | -$47.6M |
| Income tax expense | $13K+225.0% | $4K-20.0% | $5K+109.4% | -$53K |
| Net loss | -$114.3M-389.3% | -$23.4M+73.6% | -$88.4M-86.1% | -$47.5M |
| Net loss per share attributable to common stockholders - basic | -$1K-652.9% | -$170+74.6% | -$670-86.1% | -$360 |
| Net loss per share attributable to common stockholders - diluted | -$1K-652.9% | -$170+74.6% | -$670-86.1% | -$360 |
| Weighted average number of shares during the period-basic | $130.3M-2.9% | $134.2M+1.0% | $132.9M-0.0% | $132.9M |
| Weighted average number of shares during the period -diluted | $130.3M-2.9% | $134.2M+1.0% | $132.9M-0.0% | $132.9M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
Wellgistics Health, Datavault AI Agree to Form DelivMeds AI
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
Wade Defendants Dispute Complaint and Statement by Scilex Holding Company